MedTrace Logo

Bone Marrow Derived Mononuclear Cells For Myocardial Regeneration

NCT00938847 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2009-07-14

No results posted yet for this study

Summary

Evaluative pilot study for safety and feasibility with administration of autologous bone bone marrow derived mononuclear cells by endoventricular catheter into the normal border zone fo the ischemic lesion.

Conditions

  • Left Ventricular Dysfunction

Interventions

DEVICE

PCI

Stent implantation after acute myocardial infarction

Sponsors & Collaborators

  • Cordis Corporation

    collaborator INDUSTRY

  • Asklepios proresearch

    lead INDUSTRY

Principal Investigators

  • Karl-Heinz Kuck, Prof. Dr. med. · Asklepios Klinik St. Georg, Departement of Cardiology

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28
Primary Completion
2007-10-31
Completion
2008-10-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00938847 on ClinicalTrials.gov